Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P07902
UPID:
GALT_HUMAN
Alternative names:
UDP-glucose--hexose-1-phosphate uridylyltransferase
Alternative UPACC:
P07902; B4E097; E7ET32; Q14355; Q14356; Q14357; Q14358; Q14359; Q14360; Q14361; Q14363; Q14364; Q14365; Q14369; Q14370; Q14371; Q14372; Q14373; Q14374; Q14375; Q14377; Q14378; Q14380; Q14381; Q14382; Q14383; Q14384; Q14385; Q14386; Q14387; Q14389; Q16766; Q53XK1; Q5VZ81; Q96BY1
Background:
Galactose-1-phosphate uridylyltransferase, also known as UDP-glucose--hexose-1-phosphate uridylyltransferase, plays a pivotal role in galactose metabolism. This enzyme's function is crucial for converting galactose into glucose-1-phosphate, thereby preventing the accumulation of galactose in the body, which can lead to toxic effects.
Therapeutic significance:
Galactosemia 1, a severe metabolic disorder, is directly linked to mutations in the gene encoding Galactose-1-phosphate uridylyltransferase. Understanding the enzyme's role could pave the way for developing targeted therapies to manage or cure Galactosemia 1, offering hope to affected individuals.